Artelo Biosciences to Showcase ART26.12 Pain Treatment at IASP Congress
Artelo Biosciences will present its first-in-human FABP5 inhibitor ART26.12 at the IASP 2026 World Congress on Pain. The presentation will introduce ART26.12 as the first selective FABP5 inhibitor to enter human clinical st